news
Consortium established to support ICH M7 compliance
An industry work-group comprising of toxicologists, pharmaceutical companies and data experts plans to unveil the early results of a data sharing project...
List view / Grid view
Boehringer Ingelheim
news
Sanofi and Boehringer Ingelheim confirm closing of business swap date
6 June 2017 | By Niamh Marriott, Junior Editor
The strategic transaction, which consists of an exchange of Sanofi's animal health business & Boehringer Ingelheim's CHC business, has been closed in market
news
Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
news
New technology could dramatically shorten diagnosis time of stroke patients
11 May 2017 | By Sarah Wills, Editorial Assistant
An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
article
Biosimilars: the future of Pharma? An interview with Boehringer Ingelheim
3 May 2017 | By Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim
With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…
article
The top 21… wealthiest pharma companies
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
news
FDA approves drug that reduces risk of cardiovascular death in diabetics
12 December 2016 | By Niamh Louise Marriott, Digital Editor
It significantly reduced the risk of (the combined primary endpoint) cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo...
news
Boehringer Ingelheim’s bevacizumab biosimilar demonstrates bioequivalence
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BI 695502, a bevacizumab biosimilar candidate to Avastin, is a monoclonal antibody that may slow or stop the growth of certain tumour types by preventing...
news
Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib...
news
Boehringer Ingelheim and ViraTherapeutics collaborate to boost immune-oncology pipeline
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development...
news
Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...
news
Lilly and Boehringer Ingelheim take on metastatic breast cancer
13 July 2016 | By Victoria White, Digital Content Producer
Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer...
news
First patient enrolled in IPF biomarker study of Ofev
30 June 2016 | By Victoria White, Digital Content Producer
INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
news
Sanofi and Boehringer Ingelheim reach next step in business swap
27 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Boehringer Ingelheim have signed contracts to secure the exchange of Sanofi's Merial and Boehringer Ingelheim's consumer healthcare business...
news
Jardiance reduces risk of progressive kidney disease in type 2 diabetes
14 June 2016 | By Victoria White, Digital Content Producer
Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease...
